Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy

Medical Hypotheses

Volumn 66, Issue 2, 2006, Pages 273-275

  Yamagishi, S ^a   Nakamura, K ^a   Matsui, T ^a   Takeuchi, Masayoshi ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BISPHOSPHONIC ACID DERIVATIVE; GERANYLTRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; MINODRONIC ACID; NITROGEN DERIVATIVE; PYRIDOXAMINE; RAC PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ATTENUATION; DIABETIC RETINOPATHY; DISEASE COURSE; HUMAN; HYPOLIPEMIA; HYPOTHESIS; NONHUMAN; OSTEOPOROSIS; PATHOGENESIS; PRENYLATION; PRIORITY JOURNAL; RETINA; RISK; SHORT SURVEY;

ANIMALIA;

EID: 28844495585     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.08.042     Document Type: Article

References (21)

1. S. Yamagishi, and T. Imaizumi Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy Curr Pharm Des 11 2005 2279 2299
2. S. Yamagishi, M. Takeuchi, Y. Inagaki, K. Nakamura, and T. Imaizumi Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy Int J Clin Pharmacol Res 23 2003 129 134
3. M. Takeuchi, and S. Yamagishi TAGE (toxic AGEs) hypothesis in various chronic diseases Med Hypotheses 63 2004 449 452
4. M. Takeuchi, and S. Yamagishi Alternative routes for the formation of glyceraldehydes-derived AGEs (TAGE) in vivo Med Hypotheses 63 2004 453 455
5. H. Vlassara, R. Bucala, and L. Striker Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging Lab Invest 70 1994 138 151
6. A. Bierhaus, M.A. Hofmann, R. Ziegler, and P.P. Nawroth AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept Cardiovasc Res 37 1998 586 600
7. S. Yamagishi, K. Nakamura, and T. Imaizumi Advanced glycation end products (AGEs) and diabetic vascular complications Curr Diabetes Rev 1 2005 93 106
8. A.M. Schmidt, and D. Stern Atherosclerosis and diabetes: the RAGE connection Curr Atheroscler Rep 2 2000 430 436
9. M. Takeuchi, S. Yamagishi, M. Iwaki, K. Nakamura, and T. Imaizumi Advanced glycation end products (AGEs) inhibitors and their therapeutic implications in diseases Int J Clin Pharm Res 24 2004 95 101
10. S. Yamagishi, K. Nakamura, and Y. Jinnouchi Therapeutic implications of blockers of advanced glycation end products (AGEs)-their receptor (RAGE) system Int J Pharm 1 2005 203 209
11. S. Yamagishi, and M. Takeuchi Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation Drug Exp Clin Res 30 2004 169 175
12. R. Abe, T. Shimizu, and H. Sugawara Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions J Invest Dermatol 122 2004 461 476
13. S. Yamagishi, S. Amano, and Y. Inagaki Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes Biochem Biophys Res Commun 290 2002 973 978
14. T. Okamoto, S. Yamagishi, and Y. Inagaki Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin FASEB J 16 2002 1928 1930
15. D.L. Brown, and R. Robbins Developments in the therapeutic applications of bisphosphonates J Clin Pharmacol 39 1999 651 660
16. E. Van Beek, E. Pieterman, L. Cohen, C. Lowik, and S. Papapoulos Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates Biochem Biophys Res Commun 264 1999 108 111
17. R. Ylitalo, J. Kalliovalkama, and X. Wu Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro Pharmacol Toxicol 83 1998 125 131
18. M.P. Wautier, O. Chappey, and S. Corda Activation of NADPH oxidase by AGE links oxidative stress to altered gene expression via RAGE Am J Physiol Endocrinol Metab 280 2001 E685 E694
19. S. Yamagishi, R. Abe, and Y. Inagaki Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling Am J Pathol 165 2004 1865 1874
20. T. Okamoto, S. Yamagishi, and Y. Inagaki Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro Biochem Biophys Res Commun 297 2002 419 424
21. J.M. Onorato, A.J. Jenkins, S.R. Thorpe, and J.W. Baynes Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine J Biol Chem 275 2000 21177 21184